Association of neonatal withdrawal syndrome with concurrent use of multiple neuropsychiatric medications in pregnant women

IF 2 3区医学 Q2 OBSTETRICS & GYNECOLOGY

Early human development Pub Date : 2025-08-27 DOI:10.1016/j.earlhumdev.2025.106385

Miyako Nakagawa , Kosuke Doki , Mana Obata-Yasuoka , Hiromi Hamada , Daisuke Hitaka , Yayoi Miyazono , Hidetoshi Takada , Masato Homma

{"title":"Association of neonatal withdrawal syndrome with concurrent use of multiple neuropsychiatric medications in pregnant women","authors":"Miyako Nakagawa , Kosuke Doki , Mana Obata-Yasuoka , Hiromi Hamada , Daisuke Hitaka , Yayoi Miyazono , Hidetoshi Takada , Masato Homma","doi":"10.1016/j.earlhumdev.2025.106385","DOIUrl":null,"url":null,"abstract":"<div><h3>Aim</h3><div>Neonatal withdrawal syndrome is characterized by withdrawal symptoms in neonates because of the discontinuation of transplacental drug transfer after delivery. This study aimed to examine the risk factors for withdrawal symptoms to clarify the impact of the number of neuropsychiatric drugs administered during pregnancy.</div></div><div><h3>Methods</h3><div>This was a retrospective observational study including 344 neonates born to 341 mothers receiving neuropsychiatric drugs, including antipsychotics, antidepressants, antiepileptics, and anxiolytics/sedatives during pregnancy. The presence of withdrawal symptoms was assessed using the Isobe score, comprising 15 symptoms. Multivariable logistic regression analysis was performed to identify significant risk factors for the presence of withdrawal symptoms.</div></div><div><h3>Results</h3><div>Withdrawal symptoms developed in 178 (51.7 %) neonates. The frequency of neonates with withdrawal symptoms was higher in neonates born to mothers receiving ≥3 neuropsychiatric drugs compared to those born to mothers receiving 1–2 neuropsychiatric drugs (73.2 % vs. 45.0 %; <em>P</em> < 0.001). By multivariable logistic regression analysis, the presence of withdrawal symptoms was associated with the concurrent use of ≥3 neuropsychiatric drugs during pregnancy (adjusted odds ratio, 2.24; 95 % confidence interval, 1.09–4.62; <em>P</em> = 0.029) and the maternal use of antipsychotics (adjusted odds ratio, 1.77; 95 % confidence interval, 1.06–2.94; <em>P</em> = 0.028).</div></div><div><h3>Conclusions</h3><div>The concurrent use of ≥3 neuropsychiatric drugs during pregnancy and the maternal use of antipsychotics were significant risk factors for the presence of withdrawal symptoms.</div></div>","PeriodicalId":11435,"journal":{"name":"Early human development","volume":"210 ","pages":"Article 106385"},"PeriodicalIF":2.0000,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Early human development","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0378378225001951","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim

Neonatal withdrawal syndrome is characterized by withdrawal symptoms in neonates because of the discontinuation of transplacental drug transfer after delivery. This study aimed to examine the risk factors for withdrawal symptoms to clarify the impact of the number of neuropsychiatric drugs administered during pregnancy.

Methods

This was a retrospective observational study including 344 neonates born to 341 mothers receiving neuropsychiatric drugs, including antipsychotics, antidepressants, antiepileptics, and anxiolytics/sedatives during pregnancy. The presence of withdrawal symptoms was assessed using the Isobe score, comprising 15 symptoms. Multivariable logistic regression analysis was performed to identify significant risk factors for the presence of withdrawal symptoms.

Results

Withdrawal symptoms developed in 178 (51.7 %) neonates. The frequency of neonates with withdrawal symptoms was higher in neonates born to mothers receiving ≥3 neuropsychiatric drugs compared to those born to mothers receiving 1–2 neuropsychiatric drugs (73.2 % vs. 45.0 %; P < 0.001). By multivariable logistic regression analysis, the presence of withdrawal symptoms was associated with the concurrent use of ≥3 neuropsychiatric drugs during pregnancy (adjusted odds ratio, 2.24; 95 % confidence interval, 1.09–4.62; P = 0.029) and the maternal use of antipsychotics (adjusted odds ratio, 1.77; 95 % confidence interval, 1.06–2.94; P = 0.028).

Conclusions

The concurrent use of ≥3 neuropsychiatric drugs during pregnancy and the maternal use of antipsychotics were significant risk factors for the presence of withdrawal symptoms.

查看原文本刊更多论文

孕妇同时使用多种神经精神药物与新生儿戒断综合征的关系

目的新生儿戒断综合征的特点是新生儿因分娩后停止经胎盘药物转移而出现戒断症状。本研究旨在检查戒断症状的危险因素，以阐明怀孕期间服用神经精神药物数量的影响。方法本研究是一项回顾性观察性研究，包括341名母亲在怀孕期间服用神经精神药物，包括抗精神病药、抗抑郁药、抗癫痫药和抗焦虑药/镇静剂所生的344名新生儿。使用Isobe评分评估戒断症状的存在，包括15种症状。进行多变量logistic回归分析以确定出现戒断症状的重要危险因素。结果178例（51.7%）新生儿出现戒断症状。接受≥3种神经精神药物治疗的母亲所生的新生儿出现戒断症状的频率高于接受1-2种神经精神药物治疗的母亲所生的新生儿（73.2% vs 45.0%; P < 0.001）。经多变量logistic回归分析，出现戒断症状与妊娠期间同时使用≥3种神经精神药物（校正优势比2.24,95%可信区间1.09 ~ 4.62,P = 0.029）和母体使用抗精神病药物（校正优势比1.77,95%可信区间1.06 ~ 2.94,P = 0.028）相关。结论孕期同时使用≥3种神经精神药物及母体使用抗精神病药物是发生戒断症状的重要危险因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Early human development 医学-妇产科学

CiteScore

4.40

自引率

4.00%

发文量

100

审稿时长

46 days

期刊介绍： Established as an authoritative, highly cited voice on early human development, Early Human Development provides a unique opportunity for researchers and clinicians to bridge the communication gap between disciplines. Creating a forum for the productive exchange of ideas concerning early human growth and development, the journal publishes original research and clinical papers with particular emphasis on the continuum between fetal life and the perinatal period; aspects of postnatal growth influenced by early events; and the safeguarding of the quality of human survival. The first comprehensive and interdisciplinary journal in this area of growing importance, Early Human Development offers pertinent contributions to the following subject areas: Fetology; perinatology; pediatrics; growth and development; obstetrics; reproduction and fertility; epidemiology; behavioural sciences; nutrition and metabolism; teratology; neurology; brain biology; developmental psychology and screening.